Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADDXFNASDAQ:AEHAWOTCMKTS:AHROQNYSE:AMPE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shs30,000 shsAHROQAtheroNova$0.00$0.00▼$0.06N/AN/A49,080 shs150,600 shsAMPEAmpio Pharmaceuticals$0.00+3,900.0%$0.02$0.00▼$0.45$5K4.76589 shs272 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%AEHAWAesther Healthcare Acquisition0.00%-8.70%-14.43%-62.12%-80.94%AHROQAtheroNova0.00%0.00%0.00%0.00%0.00%AMPEAmpio Pharmaceuticals+3,900.00%+48.15%-96.93%+566.67%-96.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAHROQAtheroNovaN/AN/AN/AN/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals0.1492 of 5 stars0.03.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex Therapeutics 0.00N/AN/AN/AAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AAHROQAtheroNova 0.00N/AN/AN/AAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AAHROQAtheroNovaN/AN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAHROQAtheroNovaN/AN/A0.00N/AN/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAHROQAtheroNovaN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AAEHAWAesther Healthcare AcquisitionN/AAHROQAtheroNovaN/AAMPEAmpio Pharmaceuticals5.73%Insider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AAEHAWAesther Healthcare AcquisitionN/AAHROQAtheroNova34.40%AMPEAmpio Pharmaceuticals3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableAHROQAtheroNova3N/AN/ANot OptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataADDXF, AEHAW, AMPE, and AHROQ HeadlinesRecent News About These CompaniesAMPE Ampio Pharmaceuticals, Inc.June 13, 2025 | seekingalpha.comIs Ampio Pharmaceuticals (NYSE:AMPE) Making Strides in the Biotechnology Sector?February 20, 2025 | kalkinemedia.comKAmpio Announces Notice of Proposed Settlement of Stockholder Derivative Actions and Settlement HearingJanuary 30, 2025 | markets.businessinsider.comDifferentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFFNovember 13, 2024 | nai500.comNAmpio Pharmaceuticals (OTC:AMPE) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comAmpio slumps as FDA delivers knee osteoarthritis shockAugust 11, 2024 | pharmaphorum.comPAmpio Pharmaceuticals, Inc. (AMPE)May 17, 2024 | finance.yahoo.comAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationApril 3, 2024 | finance.yahoo.comAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationApril 3, 2024 | prnewswire.comAMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023March 27, 2024 | investorplace.comAmpio Pharmaceuticals IncMarch 26, 2024 | money.usnews.comAmpio prepares to wind down after final therapeutic dream diesMarch 26, 2024 | fiercebiotech.comFAmpio Pharmaceuticals, Inc.: Ampio Announces Voluntary Delisting and SEC DeregistrationMarch 26, 2024 | finanznachrichten.deUS Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence ReadingsMarch 26, 2024 | msn.comAmpio Announces Voluntary Delisting and SEC DeregistrationMarch 25, 2024 | finance.yahoo.comAmpio Pharmaceuticals, Ironwood, Incannex among healthcare moversFebruary 29, 2024 | msn.comAmpio Pharmaceuticals, Inc.: Ampio Provides Update on Results from Pre-IND Enabling StudiesFebruary 15, 2024 | finanznachrichten.deAmpio Provides Update on Results from Pre-IND Enabling StudiesFebruary 14, 2024 | prnewswire.comAmpio Pharmaceuticals Announces At-The-Market Stock OfferingJanuary 26, 2024 | msn.comSociedad Quimica Y Minera de Chile, Altice USA, Cingulate among premarket gainers' packDecember 28, 2023 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADDXF, AEHAW, AMPE, and AHROQ Company DescriptionsAddex Therapeutics OTCMKTS:ADDXF$0.99 0.00 (0.00%) As of 02/3/2023Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Aesther Healthcare Acquisition NASDAQ:AEHAW$0.0091 0.00 (0.00%) As of 07/3/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.AtheroNova OTCMKTS:AHROQAtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA.Ampio Pharmaceuticals NYSE:AMPE$0.0040 +0.00 (+3,900.00%) As of 07/7/2025 01:24 PM EasternAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
